二甲双胍在甲状腺结节伴胰岛素抵抗患者治疗中的作用:系统综述与荟萃分析
该系统综述与荟萃分析纳入5项研究共189例甲状腺结节伴胰岛素抵抗患者,评估二甲双胍治疗前后结节大小、TSH、甲状腺体积及HOMA-IR的变化。结果显示二甲双胍可轻微但显著缩小甲状腺结节,并降低TSH和HOMA-IR水平,但甲状腺体积无变化,证据质量普遍较低。
核心结论
- 二甲双胍可诱导甲状腺结节伴胰岛素抵抗患者的结节大小、TSH和HOMA-IR水平下降,但甲状腺体积无变化。
- 二甲双胍治疗甲状腺结节是否具有临床意义尚待证实。
研究设计与样本
- 系统综述与荟萃分析,文献检索共识别250条记录,最终纳入5项研究。
- 最终分析共纳入189例患者,评估结局为甲状腺结节大小、TSH水平、甲状腺体积和HOMA-IR。
- 采用随机效应模型对标准化均数差(SMD)进行荟萃分析,使用I2评估异质性,并采用GRADE指南评估证据质量。
主要发现
- 证据质量普遍评估为低或极低。
临床怎么用
- 对于甲状腺结节伴胰岛素抵抗的患者,二甲双胍可能作为辅助治疗选择,但需注意证据质量较低。
- 临床决策时应结合患者具体情况,并告知患者二甲双胍对甲状腺结节的临床意义尚不明确。
局限性
- 纳入研究数量较少(5项),总样本量有限(189例)。
- 证据质量普遍评估为低或极低。
- 二甲双胍治疗甲状腺结节的临床意义尚未证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metformin is the most-prescribed oral medication to lower blood glucose worldwide. Some data suggest that metformin may have a role in the treatment of patients with thyroid nodules, but contrasting results are reported in different settings. This study explores and critically reevaluates the knowledge on this topic. METHODS: A literature search identified 250 records. Studies evaluating the size of thyroid nodules before and after metformin treatment were included. Assessed outcomes were the size of thyroid nodules, thyrotropin (TSH) level, thyroid gland volume, and insulin resistance index (HOMA-IR). After screening and full-text assessment, five studies were included in the systematic review. Random-effects meta-analyses of the standardized mean difference (SMD) were performed for the four outcomes of interest. Heterogeneity was estimated using I2, and the quality of evidence was assessed for each outcome using the Grading of Recommendations Assessment, Development, and Evaluation guidelines. RESULTS: A total of 189 patients were included in the final analysis. After metformin treatment, a slight but significant reduction in thyroid nodule size was found in four studies, which included a total of 167 patients (SMD 0.46 [confidence interval (CI) 0.00-0.93]; p = 0.05). Similarly, in four studies reporting on a total of 146 patients, significant reductions in TSH level (SMD 0.30 [CI 0.07-0.53]; p = 0.01) and HOMA-IR level (SMD 0.90 [CI 0.12-1.67]; p = 0.02) were reported after treatment with metformin. In two studies, which included 114 patients, no change in thyroid gland volume was discovered after treatment with metformin (SMD 0.21 [CI -0.05 to 0.47]; p = 0.11). Quality of evidence was generally assessed as low or very low. CONCLUSIONS: Metformin induces reductions in thyroid nodule size and TSH and HOMA-IR levels in patients with thyroid nodules and insulin resistance. In contrast, no change in thyroid gland volumes was found. Whether metformin treatment for thyroid nodules has clinical significance remains to be demonstrated.
引用
- He X, Wu D, Hu C, et al. Role of Metformin in the Treatment of Patients with Thyroid Nodules and Insulin Resistance: A Systematic Review and Meta-Analysis. Thyroid. 2019. PMID: 30595105. doi:10.1089/thy.2017.0707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。